BASEL, Switzerland,
Sept. 20 /PRNewswire-FirstCall/ -
Neuro-Biotech Corporation (PINKSHEETS: MRES)(OTCQB: MRES) is a
worldwide biotechnological enterprise involved in the unique
international niche of clinical neuroscience diagnostic testing.
Neuro-Biotech Corp. uses proprietary molecular nanotechnology IVDDs
(in vitro diagnostic devices) for the quantitative measurement of
blood parameters to evaluate the input and output of the brain
through specific neuro-biomarkers. As a result of more than 20
years of R&D, Neuro-Biotech Corp.'s specific expertise in
clinical neurosciences applied enzymology is dedicated to the
understanding of the relationship between the neurotransmitter
families within the brain and their various influences on the
peripheral systems involving the Hypothalamo-Pituitary
Adreno-Sympathetic (HPAS) Axis. The HPAS Axis manages body
mechanisms against stressful situations in order to maintain the
homeostasis responsible for the resistance of the organism to its
psycho-socio-environment through psycho-neuro-immune and endocrine
systems.
This unique understanding of the communication between the brain
and the human body, has led to the development of in vitro
diagnostic blood tests. They are used for the detection,
prevention, monitoring and follow-up of the major stress-related,
socio-professional and occupational diseases, such as Chronic
Fatigue Syndrome (CFS), Great Anxiety (GA), Panic Syndrome (PS),
Neuropathies or Fibromyalgia (FM), Cardiovascular diseases like
Essential Hypertension or Arrhythmia, Neurodegenerative diseases
such as Alzheimer and Parkinson Diseases as well as Mental-Health
Disorders in the vein of Depression and Schizophrenia.
Neuro-Biotech Corp's goals have resulted in a new and reliable
portfolio of quantitative blood tests that provide general
practitioners and specialists useful clinical parameters for the
diagnosis of neuroscience-related diseases or physio-pathological
impairments. This is accomplished by identifying abnormal readings
of specific bio-markers within the blood or other biological
fluids. Neuro-Biotech Corp's diagnostic tests are without equal in
being non-invasive, sensitive, reliable and rapidly done as an
essential complement to current clinical laboratory testing
procedures.
Neuro-Biotech presently has the opportunity to commercialize 12
clinical Neuro Blood Tests through partnerships, as specialized
blood testing for a progressive clinical neuroscience investigation
of targeted diseases, thus selectively monitoring specific
neuro-biomarkers related to the neuro-immune and endocrine systems.
Caregivers will now be able to evaluate and establish an
individual's ability to react to stress and, to identify the
appropriate neuro-endocrine and immune dysfunctioning. By
monitoring bio-indicators related to workplace stress-related
diseases and mental-health disorders, efficient patient treatment
and follow-up are feasible.
Clinical Neuroscience-related diseases can be difficult to diagnose
and complex to treat.
If we don't know at what point an individual gets sick...and... at
what point he's better...
How can we manage the care and rehabilitation ?
Neuro-Biotech Corp. has the answer... that is...
EARLY DETECTION, MONITORING & APPROPRIATE FOLLOW-UP
Forward Looking Statements
This release contains statements that are made pursuant to the
Safe Harbor Provisions of the Private Securities Litigation Act of
1995. Certain statements in this press release may contain words
such as "anticipates," "believes," "could," "expects," "intends,"
"may," "projects," "targets" and other similar language that is
considered forward-looking statements. These forward-looking
statements are subject to certain risks and uncertainties and
persons reading this release are cautioned that such statements are
only predictions, and that the Company's actual future results or
performance may be materially different. The Company disclaims any
intention or obligation to update or revise forward-looking
information, whether as a result of new information, future events,
or otherwise, could cause the company's actual results to differ
materially from those indicated in any forward-looking
statements.
SOURCE Neuro-Biotech Corp.
Copyright . 20 PR Newswire